Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Target Raised at Bank of America

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective increased by equities research analysts at Bank of America from $908.00 to $1,030.00 in a note issued to investors on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Bank of America‘s price target would suggest a potential upside of 11.00% from the stock’s current price.

A number of other brokerages also recently issued reports on REGN. Jefferies Financial Group raised their price objective on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Wall Street Zen raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 20th. Argus raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 target price on the stock in a research report on Thursday, October 1st. Wells Fargo & Company increased their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. Finally, Citigroup increased their price objective on shares of Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the stock a “neutral” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $872.00.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $927.89 on Monday. The stock has a market capitalization of $95.54 billion, a price-to-earnings ratio of 20.49, a price-to-earnings-growth ratio of 1.57 and a beta of 0.10. The company has a quick ratio of 3.66, a current ratio of 4.06 and a debt-to-equity ratio of 0.08. Regeneron Pharmaceuticals has a twelve month low of $591.52 and a twelve month high of $935.35. The firm’s fifty day simple moving average is $793.30 and its two-hundred day simple moving average is $738.05.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The firm had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. During the same quarter in the previous year, the business posted $11.83 EPS. Regeneron Pharmaceuticals’s revenue was up 36.3% on a year-over-year basis. As a group, analysts anticipate that Regeneron Pharmaceuticals will post 49.10 earnings per share for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the sale, the executive vice president owned 13,134 shares of the company’s stock, valued at $11,163,900. This trade represents a 8.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 8,093 shares of company stock valued at $6,506,845. Corporate insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. LCM Capital Management Inc boosted its holdings in Regeneron Pharmaceuticals by 2.2% in the third quarter. LCM Capital Management Inc now owns 616 shares of the biopharmaceutical company’s stock valued at $467,000 after acquiring an additional 13 shares during the last quarter. Arjuna Capital grew its position in Regeneron Pharmaceuticals by 3.2% in the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock valued at $353,000 after purchasing an additional 14 shares in the last quarter. Oakworth Capital Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 25.0% in the 3rd quarter. Oakworth Capital Inc. now owns 70 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 14 shares during the period. Geneos Wealth Management Inc. boosted its position in Regeneron Pharmaceuticals by 1.8% during the first quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company’s stock worth $645,000 after purchasing an additional 15 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. raised its holdings in Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 69 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 16 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.